Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by B. Riley in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $20.00 target price on the stock, up from their previous target price of $11.00. B. Riley’s price objective suggests a potential upside of 202.57% from the company’s current price.

Several other brokerages also recently weighed in on TRVI. Needham & Company LLC cut their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. D. Boral Capital reissued a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday. Oppenheimer boosted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and issued a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday. Finally, Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $9.00 to $29.00 in a report on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Stock Down 2.9 %

NASDAQ:TRVI opened at $6.61 on Wednesday. The company has a market capitalization of $508.08 million, a PE ratio of -15.02 and a beta of 0.90. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.39. The stock has a fifty day simple moving average of $4.55 and a 200-day simple moving average of $3.73.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. As a group, equities analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares in the company, valued at approximately $519,075. The trade was a 51.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 24.37% of the stock is owned by company insiders.

Institutional Trading of Trevi Therapeutics

Institutional investors have recently modified their holdings of the company. Summit Investment Advisors Inc. grew its holdings in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after purchasing an additional 2,894 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Trevi Therapeutics during the 4th quarter worth about $49,000. Squarepoint Ops LLC purchased a new stake in shares of Trevi Therapeutics during the 4th quarter worth about $58,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Trevi Therapeutics during the 3rd quarter worth about $63,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.